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Abstract
Background and Aims: Recurrent infection of hepatitis C
virus (HCV) in liver transplant (LT) recipients is universal and
associated with significant morbidity and mortality. Methods:
We retrospectively evaluated the safety and efficacy of ledipas-
vir/sofosbuvir with and without ribavirin in LT recipients with
recurrent genotype 1 hepatitis C. Results: Eighty-five LT
recipients were treated for recurrent HCV with ledipasvir/
sofosbuvirwith and without ribavirin for 12 or 24 weeks. The
mean (± standard deviation [SD]) time from LT to treatment
initiation was 68 (±71) months. The mean (± SD) age of the
cohort was 63 (±8.6) years old. Most recipients were male
(70%). Baseline alanine transaminase, total bilirubin, and
HCV ribonucleic acid (RNA) values (± SD) were 76.8 (±126)
mg/dL, 0.8 (±1.3) U/L, and 8,010,421.9 (±12,420,985)
IU/mL, respectively. Five of 43 recipients who were treated
with ribavirin required drug cessation due to side effects, with
4 of those being anemia complications. No recipient discontin-
ued the ledipasvir/sofosbuvir. Eighty-one percent of recipients
had undetectable viral levels at 4 weeks after starting therapy,
and all recipients had complete viral suppression at the end of
therapy. The sustained viral response at 12 weeks after com-
pletion of therapy was 94%. Conclusion: Ledipasvir and
sofosbuvir with and without ribavirin therapy is an effective
and well-tolerated interferon-free treatment for recurrent
HCV infection after LT. Anemia is not uncommon in LT recipi-
ents receiving ribavirin.
Citation of this article: Saab S, Rheem J, Jimenez MA,
Fong TM, Mai MH, Kachadoorian CA, et al. Effectiveness of
ledipasvir/sofosbuvir with/without ribavarin in liver transplant
recipients with hepatitis C. J Clin Transl Hepatol 2017;5(2):
101–108. doi: 10.14218/JCTH.2016.00070.
Introduction
Hepatitis C virus (HCV) is the leading indication for liver
transplantation (LT) in the United States.1 Post-LT recipients
universally develop recurrent HCV infection. Recipients with
HCV have 30% higher mortality at 5 years and can develop
aggressive recurrent disease.2–4 Whereas 20% of infected
patients in the general population develop cirrhosis after 2
decades, a similar percentage of transplant recipients develop
cirrhosis after just 5 years.4–6
HCV treatment of LT recipients has substantially evolved
over the past several decades. Due to the significant side
effects associated with treatment, HCV therapy was initially
limited to patients at risk of progressive liver disease.
However, recent advances in treatment have lowered the
treatment threshold, particularly among LT recipients.7–10
Given that the sustained viral response (SVR) in the general
population is similar to that in the transplant community,
transplant recipients are no longer considered to be a difficult
to treat population.11–13
A number of all-oral antiviral therapies have been used to
treat recurrent HCV in LT recipients. These regimens differ by
their treatment duration, need for ribavirin, and potential
drug interaction.14–35 Furthermore, antiviral treatment in LT
recipients has been found to be cost effective.36 The purpose
of this study was to determine the efficacy of ledipasvir and
sofosbuvir with or without ribavirin (LDV/SOF ± RBV) in a
non-clinical trial setting. The hypothesis of our study was
that LDV/SOF ± RBV is safe and effective in LT recipients.
Methods
We performed a retrospective chart review of all adult LT
recipients who had been treated with LDV/SOF at the Uni-
versity of California Los Angeles Medical Center (UCLA)
between September 2014 and June 2016.
Inclusion criteria included age of at least 18 years at the
beginning of treatment, diagnosis of genotype 1 HCV infec-
tion, and detectable HCV ribonucleic acid (RNA) after LT.
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Quantitative PCR was used to detect the HCV RNA viral load.
A polymerase chain reaction was used to amplify the viral
target RNA followed by hybridization for HCV genotyping.
Exclusion criteria included evidence of allograft rejection on
biopsy within 6 months of starting the antiviral therapy and
critical illness (i.e. patients with circulatory shock, respiratory
failure, and acute renal failure requiring urgent dialysis) at
start of therapy.
Data were obtained by review of medical records and
review of the UCLA LT database after Institutional Review
Board approval. Demographic data (age, sex), HCV genotype,
history of LT, history of previous HCV therapy, non-liver related
medical history (active cardiopulmonary disease, hemodialy-
sis, stroke, non-liver malignancy, diabetes), co-existent liver
disease (non-alcoholic fatty liver disease [NAFLD], hepatitis B
infection, autoimmune hepatitis, hepatocellular carcinoma
[HCC]), and immunosuppressant regimen were recorded.
The presence and severity of liver fibrosis was assessed
using imaging, blood work and histology. Fibrosis-4 (FIB-4)
scores were used to determine cirrhosis in patients without
imaging and biopsy.
Transplant recipients were treated with LDV 90 mg and
SOF 400 mg in a fixed-dosed combination tablet once daily
with or without ribavirin (600 mg per day) for 12 weeks or
24 weeks. Recipients were preferably treated for 24 weeks if
they had baseline or treatment-related anemia. Anemia was
defined as hemoglobin < 12 g/dL. SVR was defined as an
undetectable HCV value at 12 weeks after treatment com-
pletion (SVR12). The SVR was calculated on an intent-to-
treat basis. The goal therapeutic range for tacrolimus was
6–10 ng/mL and for cyclosporine was 100–200 ng/mL.
A set of hematologic data, biochemical data, and HCV RNA
levels were collected at initiation of treatment, 4 weeks
after initiation of treatment (4W), end of therapy (EOT), and
12 weeks after treatment completion. Continuous variables
were presented as mean [±standard deviation (SD)], and
categorical variables were expressed as percentage. A mixed
effects model using random intercepts by recipient was used
in STATA 13 (College Station, TX, USA) to evaluate the
changes in hematologic and biochemical data at the above
defined time periods. A p-value of 0.05 or less in regression
coefficients or in pairwise comparisons between time points
was considered statistically significant.
Results
Baseline characteristics
We identified 85 consecutive LT recipients who were treated
for HCV genotype 1 using LDV/SOF ± RBV (Table 1). Eighty-
two of the recipients (96.5%) had undergone only one
LT, and three were treated after their second or third LT.
Seven recipients had undergone simultaneous liver-kidney
transplantation. Most recipients were men, and the overall
mean (± SD) age was 63.1 (± 8.6) years. Forty-six patients
(54.1%) were treatment-naïve. Eighteen patients were
treatment-experienced before orthotopic (O)LT, and 21
after OLT. Most had been treated prior with an interferon-
based antiviral regimen (69.2%). Most patients were on
tacrolimus based immunosuppressant regimen (88.2%).
The mean (±SD) time from transplantation to treatment
initiation with LDV/SOF based therapy was 68.3 (±70.6)
months. Forty-eight (57%), including a recipient with fibros-
ing cholestatic hepatitis, had a liver biopsy before starting
Table 1. Patient demographics
Parameter Result
Number of Patients 85
Age in years, mean 6 SD 63.1 6 8.6
Male, n (mean 6 SD %) 57 (70.0 6 47.3 %)
Medical history, n (%)
Active cardiopulmonary disease
y
9 (10.6%)
Hemodialysis 10 (11.8%)
Stroke 7 (8.2%)
Recent non-HCC malignancy
within 5 years
9 (10.6%)
Diabetes 27 (31.8%)
Lymphoma 1 (1.2%)
Co-existent liver disease(s), n (%)
Non-alcoholic fatty liver disease
(NAFLD)
1 (1.2%)
Hepatitis B 3 (3.9%)
Autoimmune hepatitis 1 (1.2%)
Hepatocellular carcinoma 40 (47.1%)
Mean time from LT to Treatment
Initiation in months (6SD)
68.3 (670.6)
Received more than one LT 3 (3.5%)
Treatment-naïve, n (%) 46 (54.1%)
Treatment-experienced, n (%) 39 (45.9%)
Treatment prior to LT 18 (46.2%)
Interferon/ribavirin 15 (83.3%)
Sofosbuvir/ribavirin 1 (5.6%)
Sofosbuvir/simeprevir 2 (11.1%)
Treatment post-LT 21 (53.8%)
Interferon/ribavirin 10 (47.6%)
Sofosbuvir/interferon/ribavirin 2 (9.5%)
Sofosbuvir/ribavirin 4 (19.0%)
Sofosbuvir/simeprevir 6
ribavirin
4 (19.0%)
Ribavirin monotherapy 1 (4.8%)
Stage of fibrosis at start of
treatment, n (%)
0-1 33 (38.8%)
2-3 18 (21.2%)
4 34 (40%)
Presence of fibrosing cholestatic
hepatitis
1 (1.2%)
Immunosuppression
therapy, n (%)
Tacrolimus only 30 (35.3%)
Tacrolimus +
mycophenolate 6 prednisone
39 (45.9%)
Tacrolimus + sirolimus 6
prednisone
6 (7.1%)
(continued )
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antiviral therapy. Almost half the LT recipients had a diagnosis
of cirrhosis (n = 34, 40%) prior to treatment initiation. The
diagnosis of HCC was the indication for LT in 37 (37/40) of
the recipients. A diagnosis of HCC was made incidentally at
the time of surgery in 3 (3/40) of the recipients. Out of the
10 (11.8%) recipients on dialysis, 6 (60%) were treated with
LDV/SOF without ribavirin. Twenty (74.1%) of the recipients
with baseline anemia were treated with LDV/SOF without
ribavirin. Baseline laboratory values are shown in Table 2.
Fifty-one recipients were started on LDV/SOF ± RBV with a
goal duration of 12 weeks, and treatment was extended in
4 recipients due to detectable HCV viral levels at week 4 of
treatment (Fig. 1). All 4 of these recipients were also being
treated with ribavirin. Thirty-four patients of the entire cohort
of 85 recipients received LDV/SOF ± RBV with a goal duration
of 24 weeks. No interruptions in antiviral therapy occurred in
any of the recipients.
Biochemical and HCV RNA viral response
From baseline to 12 weeks post-treatment, there was a
statistically significant decrease in the alanine transaminase
(ALT) and total bilirubin levels. The mean (±SD) ALT value
decreased from 76.8 (± 126) IU/L to 27.6 (± 24.5) IU/L
(p = 0.001). The mean (±SD) baseline serum HCV RNA was
8,010,421.9 IU/mL (±12,420,985) (Table 2). Eighty-one of
the 85 recipients had their viral load measured at 4 weeks of
treatment. HCV RNA was undetectable in 65 recipients,
detectable but unquantifiable in 5 recipients, and quantifi-
able in 11 recipients. The viral load was undetectable in
all patients at the end of treatment. Eighty (94.1%) recipi-
ents achieved SVR 12 (Table 4, Fig. 2). Thirty-one of the
34 (91.2%) patients with cirrhosis achieved SVR12 with
antiviral therapy. Forty-nine of 51 (96.1%) patients
without cirrhosis achieved SVR12. Thirty-eight of the HCC
recipients achieved SVR12 (95%). The two patients that
did not achieve SVR had HCC as an indication for LT. The
SVR12 in recipients without a diagnosis of HCC was 93%.
There was no statistically significant difference in SVR12
between cirrhotic and non-cirrhotic patients (p = 0.385)
and between HCC and non-HCC recipients (p = 1).
Five recipients experienced viral relapse. Viral relapse
occurred in all recipients within 4 weeks of completing
antiviral therapy. Four recipients were retreated and achieved
SVR12 with alternative treatment regimens (Table 3). The
fifth recipient expired due to primary lung cancer. Resistance
associated mutations were assessed after viral relapse with
Table 1. (continued)
Parameter Result
Cyclosporine only 3 (3.5%)
Cyclosporine + mycophenolate 4 (4.7%)
Sirolimus + mycophenolate 2 (2.4%)
Sirolimus + prednisone 1 (1.2%)
Treatment regimen, n (%)
Sofosbuvir/ledipasvir for
12 weeks
18 (21.2%)
Sofosbuvir/ledipasvir + ribavirin
for 12 weeks
33 (38.8%)
Sofosbuvir/ledipasvir for
24 weeks
29 (34.1%)
Sofosbuvir/ledipasvir + ribavirin
for 24 weeks
5 (5.9%)
Abbreviations: COPD, chronic obstructive pulmonary disease; HCC, hepatocellular
carcinoma; NAFLD, nonalcoholic fatty liver disease; SD, standard deviation; LT,
liver transplantation.
yExamples of active cardiopulmonary diseases include coronary artery disease,
heart failure, chronic obstructive pulmonary disease, and idiopathic pulmonary
fibrosis.
Table 2. Mean (and standard deviation) of laboratory values
Laboratory test Baseline 4 Weeks EOT SVR12 Pt Diff p-Value
Platelet count
(x1000 cells/mL)
143.4 6 59.1 160.1 6 65.6 159.9 6 76.1 152.6 6 67.5 9.2 (9.2) 0.054
Albumin (g/dL) 4.1 6 1.2 4.1 6 0.4 4.1 6 0.4 4.1 6 0.5 0 (0) 0.822
AST (U/L) 62.4 6 79.5 25.0 6 13.9 25.6 6 20.3 28.2 6 22.3 −34.3 (−34.3) <0.001
ALT (U/L) 76.8 6 126 25.2 6 19.2 24.6 6 21.7 27.6 6 24.5 −49.3 (−49.3) 0.001
Total bilirubin (mg/dL) 0.8 6 1.3 0.9 6 0.7 0.9 6 1.2 0.7 6 0.9 −0.1 (−0.1) 0.453
Serum creatinine (mg/dL)
y
1.3 6 0.4 1.3 6 0.4 1.3 6 0.4 1.3 6 0.4 0 (0) 0.514
Alkaline
phosphatase (U/L)
129.5 6 175.3 111.4 6 176.7 99.6 6 53.6 124.2 6 134.7 −5.3 (−5.3) 0.694
Hemoglobin (g/dL) 12.8 6 1.7 11.9 6 2.3 12.0 6 2.1 13.2 6 1.8 0.3 (0.3) 0.033
In patients with
RBV therapy
13.2 6 1.3 11.5 6 2.1 12.0 6 1.7 13.4 6 1.6 0.2 (0.2) 0.477
In patients without
RBV therapy
12.5 6 2.0 12.3 6 2.5 12.1 6 2.5 13.0 6 2.0 0.5 (0.5) 0.017
Abbreviations: EOT, end of treatment; SVR12, sustained viral response at 12 weeks; AST, aspartate transaminase; ALT, alanine transaminase; Pt Diff, point difference.
*Baseline vs. SVR12 paired t-test.
yPatients on dialysis were not included in the calculation of mean and standard deviation for serum creatinine.
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LDV/SOF. Their characteristics and outcomes are shown in
Table 3.
There was a statistically significant change in the distribu-
tion of fibrosis stage as determined by FIB-4 scores, between
the start of treatment and SVR12 (p < 0.001) (Fig. 3). The
number of recipients with stage 0-1 at baseline and SVR12
was 7 (8%) and 21 (25%), respectively. The number of recip-
ients with cirrhosis at baseline and SVR12 was 32 (38%) and
20 (24%), respectively.
Safety
Anemia was the most common safety issue in our cohort
treated with LDV/SOF with ribavirin. Five of the 43 recipients
required ribavirin cessation and their treatment with LDV/SOF
monotherapy was extended for a total treatment duration
of 24 weeks. Anemia occurred within 4 weeks of starting
therapy in 4 of the recipients. One patient discontinued
Fig. 1. Patient disposition.
Abbreviations: LDV, ledipasvir; SOF, sofosbuvir; RBV, ribavirin; SVR, sustained viral response.
Fig. 2. Overall viral kinetics.
Abbreviation: SVR, sustained viral response.
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ribavirin because of potential anemia given underling chronic
kidney disease (stage II) and his advanced age. However, the
patient did not develop anemia during ribavirin therapy. All
the recipients who developed anemia were 64 years of age
or older. No transplant recipient required erythropoietin-
stimulating agents or a blood transfusion. No transplant
recipients discontinued LDV/SOF for adverse effects.
Discussion
The results of our study highlight the efficacy, safety and
tolerability of LDV/SOF in LT recipients. The SVR12 in our
cohort was 94%, and no patient developed adverse side-
effects related to LDV/SOF. In contrast, the use of ribavirin,
even at non-weight based dosing, was associated with
significant anemia in 4 of 43 ribavirin recipients. None of the
patients in our cohort required admission, erythropoietin-
stimulating agents, or a blood transfusion.
The results of our study add to the increasing body of
literature supporting the role of direct-acting agents (DAAs) in
LT recipients. Potentially, LT recipients may represent a cohort
of patients in which HCV may be completely eliminated.
Indeed, the combined guidance position paper by the Amer-
ican Association for the Study of Liver Diseases (commonly
known as AASLD) and Infectious Diseases Society of America
(commonly known as IDSA) places LT recipients at the
highest priority for antiviral therapy.10 Until recently, liver
biopsies were routinely performed in LT recipients since inter-
feron–based therapy was associated with substantial adverse
effects. Today, multiple antiviral regimens are available with
comparable SVR12 (Table 4). There are important differences
among the strategies, such as need for ribavirin, duration of
treatment, and potential drug interactions. Furthermore,
some DAAs are contraindicated in decompensated liver
disease and in patients with compromised renal function.37–40
Treatment of HCV in LT recipients is an evolving field. When
we started utilizing DAAs in transplant recipients, there were
no DAA regimens approved for patients with advanced kidney
disease. Recently, two regiments were approved by the
Federal Drug Administration in patients undergoing hemodial-
ysis: a) dasabuvir plus ombitasvir, paritaprevir, and ritonavir;
and b) elbasvir and grazoprevir. However, there is a paucity
of experience using elbasvir and grazoprevir in LT recipients
and there are substantial drug interactions with dasabuvir
plus ombitasvir, paritaprevir, and ritonavir which limit currentTa
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Fig. 3. Fibrosis-4 score at baseline and SVR12.
Abbreviations: FIB-4, fibrosis-4 score; SVR, sustained viral response.
Journal of Clinical and Translational Hepatology 2017 vol. 5 | 101–108 105
Saab S. et al: Sofosbuvir/ledipasvir in LT recipients
use.41 In our early experience, we decided to proceed with
sofosbuvir-based regimens, even in patients on hemodialysis
if we felt the benefits outweighed the risks. Indeed, 10 recip-
ients on our study were on dialysis. The decision to proceed
with treating patients on hemodialysis was based on earlier
experience.42
An important area of discussion is the timing of antiviral
therapy.43 The efficacy of antiviral therapy is well established
in LT recipients. An important caveat is that relatively early
treatment is preferable since some strategies appear to have
a drop off in SVR12 with increasing amount of liver damage.16
In particular, outcomes are significantly better when initiated
early in the course of fibrosing cholestatic hepatitis.32,44
Another option is to treat patients before LT. Many providers
have based their views on the experience of hepatitis B virus
therapy in patients with advanced disease who had remark-
able improvement in liver function with viral suppression.45–47
In fact, data from a recent publication suggests that liver
function may stabilize provided that the model of end-
Stage liver disease (commonly known as MELD) is less than
15 and select patients may indeed be removed from the
transplant list.48 On the other hand, renal insufficiency,
Table 4. Summary of major trials evaluating direct-acting agents for recurrent HCV infection in post-liver transplants
AuthorRef Genotype Therapy Duration in weeks n SVR
Charlton et al.14 1, 3, 4 SOF/RBV 24 40 70% (55–73%)*
Forns et al.15 1-4 SOF/RBV 24–48 92 59% (43–73%)
z
Charlton et al.16 1, 4 LDV/SOF/RBV 12 116 92%
y
(60–100%)
yy
24 113 95%
y
(75–100%)
yy
Manns et al.17 1 LDV/SOF/RBV 12 100 95%
y
(50–100%)
yy
24 99 98%
y
(80–100%)
yy
Elfeki et al.18 1 LDV/SOF 12 32 100%
24 14 100%
Kwok et al.19 1 LDV/SOF 8 7 86%
12 69 94%
24 41 95%
1-4 LDV/SOF/RBV 12 39 97%
24 6 100%
Omichi et al.20 1 LDV/SOF 18 18 100%
1 ASV/DCV 24 9 100%
Saab et al.21 1 SOF/SIM 12 30 93%
Khemichian et al.22 1 SOF/SIM 12 32 94%
Pungpapong et al.23 1 SOF/SIM/RBV 12 105 90%
Gutierrez et al.24 1 SOF/SIM/RBV 12 61 93%
Punzalan et al.25 1 SOF/SIM 12 42 95%
Crittenden et al.26 1 SOF/SIM/RBV 12 56 88%
Brown et al.27 1 SOF/SIM/RBV 12 151 88%
Jackson et al.28 1 SOF/SIM 12 67 88%
Kwo et al.29 1 OBV/DSV/PTV/r 24 34 97%
Flisiak et al.30 1, 4 OBV/DSV/PTV/r 24 21 100%
Poordad et al.31 1 SOF/DCV/RBV 12 41 95%
Leroy et al.32 1, 4 SOF/RBV 12 8 88%
1, 3, 4 SOF/DCV 12 15 100%
Coilly et al.33 1-5 SOF/DCV6RBV 12, 24 137 96% (75–100%)**
Dumortier et al.34 1-5 SOF/DCV/RBV 12–24 125 93% (92–94%)
yy
Welzel et al.35 1-5 SOF/DCV/RBV 24 85 94% (92–100%)*
Abbreviations: HCV, hepatitis C virus; SVR, sustained viral response; SOF, sofosbuvir; SIM, simeprevir; LDV, ledipasvir; RBV, ribavirin; ASV, asunaprevir; DCV, daclatasvir;
DSV, dasabuvir; OBV, ombitasvir; PTV/r, paritaprevir with ritonavir; n/N, sample size/population size.
*Ranges in parenthesis represent SVR12 in patients with different genotypes.
zRanges in parenthesis represent SVR12 in patients treated <12 months or >12 months after liver transplantation.
ySVR12 was calculated by adding all responders in different Child-Turcotte-Pugh groups, divided by the study population.
yyRanges in parenthesis represent different SVR12 in various groups of cirrhosis.
**Ranges in parenthesis represent SVR12 in patients with or without ribavirin, treated for either 12 weeks or 24 weeks.
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inability to use HCV-positive grafts, lower SVR in patients
with advanced liver disease, and possible viral resistance
with relapse are several factors that may temper widespread
enthusiasm for treating patients before LT.49
Our study has a number of limitations. First, the cohort is
from a single center and may not be generalizable to other
institutions. Nevertheless, we treated consecutive patients
who represent the spectrum of LT recipients with cirrhosis and
are treatment experienced. Another limitation is the lack of a
control group. We do not feel the absence of a control group is
a serious detriment to our study particularly given the lack of
noticeable adverse effects that impact drop out from the
study. Larger studies may uncover unfavorable side effects
not identified in this study. Another limitation of our study is
the heterogeneity of our drug regimens. Most of the time, the
final drug regimen was determined after discussion with
health care providers since recipients were often treated
before the official guidance on LT recipients was published.
On the other hand, the results of the study represent an early
real-life experience with LDV/SOF.
The results of our single center, non-clinical trial, real world
experience demonstrate the safety, efficacy, and tolerability
of LDV/SOF with and without ribavirin in post-LT patients. This
combination of DAAs should be considered in LT recipients
with recurrent HCV who are candidates for antiviral therapy.
Further studies are needed to compare the utility of LDV/SOF
with other non-interferon based therapies.
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